Crenolanib is an inhibitor of FLT3 and PDGFR that exhibits anticancer chemotherapeutic activity. Crenolanib inhibits cell proliferation and induces apoptosis in non-small cell lung cancer (NSCLC) and acute myelogenous leukemia (AML) cells. In animal models of NSCLC, crenolanib inhibits tumor growth.
| Cas No. | 670220-88-9 |
|---|---|
| Purity | ≥98% |
| Formula | C26H29N5O2 |
| Formula Wt. | 443.54 |
| Synonym | CP-868596 |
| Solubility | 10 mM in DMSO |
| Appearance | Off white to faint yellow powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Wang P, Song L, Ge H, et al. Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits tumor growth in vivo. Onco Targets Ther. 2014 Sep 26;7:1761-8. PMID: 25328409.
Smith CC, Lasater EA, Lin KC, et al. Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5319-24. PMID: 24623852.
Zimmerman EI, Turner DC, Buaboonnam J, et al. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. Blood. 2013 Nov 21;122(22):3607-15. PMID: 24046014.
